Fulcrum Therapeutics (FULC) Q2 2026 earnings summary

Executive summary

• Discontinued clinical development of pociredir for sickle cell disease after FDA feedback left no viable regulatory path forward, leading to a comprehensive review of strategic alternatives including potential merger, acquisition, or asset sale.

• Implemented a restructuring plan reducing workforce by 85% (from 57 to 9 employees), ceasing all research and development activities, and initiating efforts to exit leased facilities.

• Engaged Leerink Partners LLC as financial advisor to assist in evaluating strategic alternatives.

• Accumulated deficit reached $639.3 million as of June 30, 2026.

Financial highlights

• Net loss for the six months ended June 30, 2026 was $45.1 million, compared to $35.0 million for the same period in 2025.

• Total operating expenses for the six months ended June 30, 2026 were $51.5 million, up from $40.2 million year-over-year, driven by impairment and restructuring charges.

• Cash, cash equivalents, and marketable securities totaled $318.8 million as of June 30, 2026.

• No revenue generated from product sales; future revenue dependent on strategic transactions or resumption of R&D.

Outlook and guidance

• Operating expenses and cash burn expected to decrease substantially following restructuring, offset in the near term by restructuring, lease exit, and advisory costs.

• Existing cash resources expected to fund operations for at least 12 months from the reporting date.

• No timeline set for completion of strategic review; possible outcomes include merger, asset sale, or dissolution.